<i>SLCO2B1</i>and<i>SLCO1B3</i>May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer - Concepedia

Concepedia

Publication | Open Access

<i>SLCO2B1</i>and<i>SLCO1B3</i>May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

DOI Full Paper Access

160

Citations

23

References

2011

Year

Ming Yang, Wanling Xie, Elahe A. Mostaghel, Mari Nakabayashi, Lillian Werner, Tong Sun, Mark M. Pomerantz, Matthew L. Freedman, Robert W. Ross, Meredith M. Regan,

Journal of Clinical Oncology

Abstract

Genetic variants of SLCO2B1 and SLCO1B3 may function as pharmacogenomic determinants of resistance to ADT in prostate cancer.

References

	Year	Citations

Page 1